What is the difference between cannabinoids and Tetrahydrocannabinol (THC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Understanding Cannabinoids vs. THC

Cannabinoids are a broad class of chemical compounds that includes THC as one specific member, along with hundreds of other compounds found in cannabis plants or synthesized in laboratories. 1

Key Definitions

Cannabinoids (The Umbrella Term)

  • Cannabinoids encompass all compounds that interact with endocannabinoid receptors throughout the central and peripheral nervous system, immune cells, and organs 1

  • This broad category includes three main types:

    • Endocannabinoids: naturally produced by the human body 1
    • Phytocannabinoids: plant-derived compounds from Cannabis sativa, including THC and CBD 1
    • Synthetic cannabinoids: laboratory-created compounds that mimic natural cannabinoids 2, 3
  • The cannabis plant contains hundreds of bioactive cannabinoid compounds, including dozens of phytocannabinoids, phenols, and terpenes 1

THC (One Specific Cannabinoid)

  • Δ9-tetrahydrocannabinol (THC) is the primary psychoactive cannabinoid responsible for the euphoric "high" associated with cannabis use 1
  • THC functions as a partial agonist at both CB1 and CB2 cannabinoid receptors in the brain and body 1
  • Under U.S. federal law, cannabis containing more than 0.3% THC is classified as marijuana, while plants with ≤0.3% THC are classified as hemp 1

Critical Clinical Distinctions

CBD: Another Major Cannabinoid

  • Cannabidiol (CBD) is the second most studied cannabinoid and produces psychoactive effects without inducing euphoria 1
  • CBD is not an agonist at CB1 or CB2 receptors; rather, it acts as a negative allosteric modulator and has been shown to reduce adverse effects of THC 1
  • CBD mechanisms include increasing endocannabinoid signaling, enhancing serotonin receptor 1A activity, and activating pain-sensing receptors 1

Potency and Composition Variability

  • THC concentration in cannabis has nearly doubled from 9% in 2008 to 17% in 2017, with some concentrates reaching 70% THC 1, 4
  • The specification and concentration of cannabinoids vary dramatically by cannabis strain and product, making effects unpredictable 1
  • Cannabis products work through the "entourage effect"—complicated synergistic and inhibitory interactions between multiple cannabinoids, terpenes, and other compounds 1

Pharmacological Differences

Metabolism

  • All cannabinoids, including THC, are metabolized through the liver's cytochrome P450 enzyme system (primarily CYP3A4 and CYP2C9) 5
  • When THC is ingested orally, it undergoes first-pass metabolism into 11-hydroxy-THC, a more potent psychoactive metabolite than THC itself 5
  • Different cannabinoids have varying bioavailability: inhaled THC is 10-35% bioavailable versus only 4-12% for oral THC 1

Synthetic Cannabinoids: A Dangerous Subset

  • Synthetic cannabinoids typically have increased affinity and efficacy at CB1 receptors compared to natural THC, making them more potent and dangerous 2
  • While THC is a relatively weak CB1 partial agonist, most synthetic cannabinoids are full agonists, resulting in more powerful effects and increased risk of adverse reactions 2
  • Synthetic cannabinoids marketed as "Spice" or "K2" can cause intoxication, withdrawal, psychosis, and death—effects rarely seen with natural cannabis 3

Clinical Implications

Drug Interactions

  • Cannabis and cannabinoids inhibit multiple CYP450 enzymes, creating potential for drug-drug interactions with medications metabolized through these pathways 1, 5
  • High-risk interactions include warfarin (very high risk), buprenorphine, and tacrolimus (high risk) 1, 5

Therapeutic Applications

  • Synthetic cannabinoids like dronabinol (synthetic THC) and nabilone are FDA-approved for specific medical indications, particularly chemotherapy-induced nausea and vomiting 1
  • Evidence suggests cannabinoids may have utility in chronic pain, chemotherapy-induced nausea, multiple sclerosis spasticity, and fibromyalgia 1

Common Pitfall

  • Clinicians and patients often mistakenly believe "cannabinoids" and "THC" are interchangeable terms, leading to confusion about product selection, dosing, and expected effects 1
  • The variable composition of cannabis products means evidence for one cannabinoid (like THC) cannot be extrapolated to whole-plant cannabis or other cannabinoid formulations 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Beyond THC: The New Generation of Cannabinoid Designer Drugs.

Frontiers in behavioral neuroscience, 2011

Guideline

Marijuana Clearance from the Body

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Cannabis Metabolism and Clinical Implications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.